Company: MBIO
Filing Date: 2025-01-15
Form Type: S-1
Source: 0001410578-25-000028
Chunk: 14

Company: MUSTANG BIO, INC.
Filing Date: 2025-01-15
Form: S-1
Chunk 14
---
. By decision dated November 8, 2024, the Panel granted our request for an extension to evidence compliance with all applicable criteria for continued listing on the Nasdaq Capital Market, including the Bid Price Rule, through January 31, 2025, and the Equity Rule through February 18, 2025. We are considering all available options that may enable us to timely evidence compliance with the continued listing criteria and maintain our listing on Nasdaq. There can be no assurance that we will be successful in our efforts to maintain the listing of our common stock on the Nasdaq Capital Market. Reverse Stock Split On January 14, 2025, we announced that we will effect a 1-for-50 reverse stock split of our issued and outstanding common stock. The reverse stock split was approved on June 27, 2024 by our board of directors and stockholders representing approximately 56% of the voting power of our outstanding capital stock, with the authorization to determine the final ratio having been granted to our board of directors. The reverse stock split is intended to bring the Company into compliance with Nasdaq’s Bid Price Rule. The reverse stock split will be effected on our common stock by the filing of a certificate of amendment (the “Amendment”) to our amended and restated certificate of incorporation, as amended, with the Secretary of State of the State of Delaware on January 15, 2025, without any change to par value. The Amendment will become effective upon such filing. No fractional shares will be issued in connection with the reverse stock split as all fractional shares will be rounded down to the next whole share. Corporate Information We are a majority-controlled subsidiary of Fortress Biotech, Inc. (“Fortress”). We were incorporated under the laws of the State of Delaware on March 13, 2015. Our principal executive offices are located at 377 Plantation Street, Worcester, Massachusetts 01605, and our telephone number is 781-652-4500. We maintain a website on the Internet at www.mustangbio.comand our e-mail address is info@mustangbio.com. Information on our website, or any other website, is not incorporated by reference in this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. Implications of Being a Smaller Reporting Company We are a smaller reporting company as defined in the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We may take advantage of certain of the scaled disclosures available to smaller